Evidence map›Paper›PMID 36147625›Full record

ArticleEClinicalMedicine2022

Time trends in tuberculosis mortality across the BRICS: an age-period-cohort analysis for the GBD 2019.

Zhiyong Zou, Guangqi Liu, Simon I Hay, Saurav Basu, Uzma Iqbal Belgaumi, Arkadeep Dhali, Sameer Dhingra, Ginenus Fekadu, Mahaveer Golechha, Nitin Joseph and 15 more

Open access · goldAbstract read
In one paragraph

Article in EClinicalMedicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
15.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 60 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Applying Multiple Analyses to Quantify Changes in the Global, Regional, and National Burden of Tuberculosis From 1990 to 2021 and the Forecast Until 2035.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2025
    Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 17 institutions in 9 countries.

Zhiyong ZouSchool of Public Health, Peking University, Beijing, China.
Guangqi LiuSchool of Public Health, Peking University, Beijing, China.
Simon I HayInstitute for Health Metrics and Evaluation; Department of Health Metrics Sciences, School of Medicine, University of Washington, Seattle, WA, USA.
Saurav BasuDepartment of Academics, Indian Institute of Public Health, Gurgaon, India.
Uzma Iqbal BelgaumiDepartment of Oral Pathology and Microbiology, Krishna Institute of Medical Sciences Deemed To Be University, Karad, India.
Arkadeep DhaliDepartment of GI Surgery, Institute of Post-Graduate Medical Education and Research and Seth Sukhlal Karnani Memorial Hospital, Kolkata, India.
Sameer DhingraDepartment of Pharmacy Practice, National Institute of Pharmaceutical Education and Research, Hajipur, India.
Ginenus FekaduSchool of Pharmacy, The Chinese University of Hong Kong, Hong Kong, China.
Mahaveer GolechhaDepartment of Health Systems and Policy Research, Indian Institute of Public Health, Gandhinagar, India.
Nitin JosephDepartment of Community Medicine, Manipal Academy of Higher Education, Mangalore, India.
Kewal KrishanDepartment of Anthropology (Prof K Krishan PhD), Panjab University, Chandigarh, India.
Francisco Rogerlândio Martins-MeloCampus Caucaia, Federal Institute of Education, Science and Technology of Ceará, Caucaia, Brazil.
Sumaira MubarikDepartment of Epidemiology and Biostatistics, Wuhan University, Wuhan, China.
Osaretin Christabel OkonjiSchool of Pharmacy, University of the Western Cape, Cape Town, South Africa.
Mahesh P ADepartment of Respiratory Medicine, Jagadguru Sri Shivarathreeswara Academy of Health Education and Research, Mysore, India.
Priya RathiKasturba Medical College, Mangalore, Manipal Academy of Higher Education, Manipal, India.
Ranjitha S ShettyDepartment of Community Medicine, Manipal Academy of Higher Education, Manipal, India.
Paramdeep SinghDepartment of Radiodiagnosis, All India Institute of Medical Sciences, Bathinda, India.
Surjit SinghDepartment of Pharmacology, All India Institute of Medical Sciences, Jodhpur, India.
Pugazhenthan ThangarajuDepartment of Pharmacology, All India Institute of Medical Sciences, Raipur, India.
Ziyue WangDepartment of Family Medicine, McGill University, Montreal, QC, Canada.
Mikhail Sergeevich ZastrozhinDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.
Christopher J L MurrayInstitute for Health Metrics and Evaluation; Department of Health Metrics Sciences, School of Medicine, University of Washington, Seattle, WA, USA.
Hmwe Hmwe KyuInstitute for Health Metrics and Evaluation; Department of Health Metrics Sciences, School of Medicine, University of Washington, Seattle, WA, USA.
Yangmu HuangSchool of Public Health, Peking University, Beijing, China.
Peking University · CNManipal Academy of Higher Education · INUniversity of Washington · USIndian Institute of Public Health Gandhinagar · INAll India Institute of Medical Sciences · INAll India Institute of Medical Sciences Jodhpur · INAll India Institute of Medical Sciences Raipur · INChinese University of Hong Kong · HKInstitute of Post Graduate Medical Education and Research · INInstituto Federal de Educação, Ciência e Tecnologia do Ceará · BRJSS Academy of Higher Education and Research · INKrishna Institute of Medical Sciences · INNational Institute of Pharmaceutical Education and Research · INPanjab University · INUniversity of California, San Francisco · USUniversity of the Western Cape · ZAWuhan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Tuberculosis is the leading cause of death from a single infectious agent among the HIV-negative population and ranks first among the HIV-positive population. However, few studies have assessed tuberculosis trends in Brazil, Russia, India, China and South Africa (BRICS) or with an emphasis on HIV status. This study assesses the time trends of tuberculosis mortality across the BRICS with an emphasis on HIV status from 1990 to 2019. Methods: We obtained tuberculosis data from the Global Burden of Disease 2019 study (GBD 2019). We calculated the relative proportion of tuberculosis to all communicable, maternal, neonatal, and nutritional diseases by HIV status across the BRICS. We used age-period-cohort modelling to estimate cohort and period effects in tuberculosis from 1990 to 2019, and calculated net drift (overall annual percentage change), local drift (annual percentage change in each age group), longitudinal age curves (expected longitudinal age-specific rate), and period (cohort) relative risks. Findings: There were 549,522 tuberculosis deaths across the BRICS in 2019, accounting for 39.3% of global deaths. Among HIV-negative populations, the age-standardised mortality rate (ASMR) of tuberculosis in BRICS remained far higher than that of high-income Asia Pacific countries, especially in India (36.1 per 100 000 in 2019, 95% UI [30.7, 42.6]) and South Africa (40.1 per 100 000 in 2019, 95% UI [36.8, 43.7]). China had the fastest ASMR reduction across the BRICS, while India maintained the largest tuberculosis death numbers with an annual decrease much slower than China's (-4.1 vs -8.0%). Among HIV-positive populations, the ASMR in BRICS surged from 0.24 per 100 000 in 1990 to 5.63 per 100 000 in 2005, and then dropped quickly to 1.70 per 100 000 in 2019. Brazil was the first country to reverse the upward trend of HIV/AIDS-tuberculosis (HIV-TB) mortality in 1995, and achieved the most significant reduction (-3.32% per year). The HIV-TB mortality in South Africa has realised much progress since 2006, but still has the heaviest HIV-TB burden across the BRICS (ASMR: 70.0 per 100 000 in 2019). We also found unfavourable trends among HIV-negative middle-aged (35-55) adults of India, men over 50 in the HIV-negative population and whole HIV-positive population of South Africa, and women aged 45-55 years of Russia. China had little progress in its HIV-positive population with worsening period risks from 2010 to 2019, and higher risks in the younger cohorts born after 1980. Interpretation: BRICS' actions on controlling tuberculosis achieved positive results, but the overall improvements were less than those in high-income Asia Pacific countries. BRICS and other high-burden countries should strengthen specified public health approaches and policies targeted at different priority groups in each country. Funding: National Natural Science Foundation of China (82073573; 72074009), Peking University Global Health and Infectious Diseases Group.

Indexed as

BRICSHIV-negativeHIV-positiveMortalityTuberculosis

Identifiers

PMID36147625
PMCPMC9486016
OpenAlexW4296116604

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.